目的 比较ALDH1+和CD44+/CD24-作为人乳腺癌干细胞标志物时在基因亚型中的分布及与临床相关因素相关方面的异同,并了解两种标志物互补后在基因亚型中的分布和临床因素的相关性.方法 采用免疫组织化学单染、双染技术检测203例未接受放化疗乳腺癌患者肿瘤组织中重叠表达ALDH1+、CD44+/CD24-表型的情况.结果 所有乳腺癌组织中重叠表达ALDH1+/CD44+/CD24-表型为5％,主要存在于HER-2(18％)型和Triple negativ型(45％),病理类型主要为浸润性导管癌,其2年无病生存率低于其他表型(P＜0.05).结论 少数乳腺癌患者(5％)为ALDH1+/CD44+/CD24-/low表型,主要存在于Triple negative 型,病理类型主要为浸润性导管癌,2年无病生存率低于其他表型.ALDH1+和CD44+/CD24-可能标志不同层次的乳腺癌干细胞,未来采用免疫组织化学技术互补检测ALDH1+和CD44+/CD24-可能预测患者预后.%Objective To compare the differences and similarities of the breast cancer stem cell makers, ALDH1+ and CD447CD24- ,in gene subtypes and clinical correlated factors,and to investigate the distribution in gene subtypes of the two complementary markers and the clinical correlation. Methods Double-staining immunohistochemistry (IHC) and single-staining IHC were applied to test the overlapped expression of ALDH1+ and CD44+/CD24- phenotypes in cancer tissues of 203 breast cancer patients who had not received chemotherapy. Results 5% breast cancer patients showed overlapped expression of ALDH1 7CD44+/CD24- phenotype which was mainly found in HER-2 type (18%) and Triple negative type (45%), with a main pathological type of invasive ductal carcinoma,and the 2-year disease-free survival rate was lower than other phenotypes (P < 0.05). Conclusion Only a small part of the breast cancer patients were of ALDH1+/CD44+/ CD24-/km phenotype which mainly existed in Triple negative type,and the main pathological type was invasive ductal carcinoma,the 2-year disease-free survival rate was low. ALDH1+ and CD44+/CD24- may mark different levels of breast cancer stem cells, therefore, ALDH1+ and CD44+/CD24- detection by complementary immunohistochemical techniques may predict patient prognosis.
展开▼
